Skip to content
Search

Latest Stories

Researchers try to crack genetic riddle of Covid-19

The UK researchers will study the genes of thousands of ill Covid-19 patients to try to crack one of the most puzzling riddles of the novel coronavirus: why does it kill some people but give others not even a mild headache?

Researchers from across the UK will sequence the genetic code of people who fell critically ill with Covid-19 and compare their genomes with those who were mildly ill or not ill at all.


The hunt for the specific genes that could cause a predisposition to getting ill with Covid-19 will involve up to 20,000 people currently or previously in hospital intensive care with Covid-19 and about 15,000 people with mild symptoms.

Scientists caution that their knowledge of the novel coronavirus, which emerged in China last year, is still modest though they say it is striking how it can be so deadly for some but so mild for others.

It is, as yet, unclear why.

"We think that there will be clues in the genome that will help us understand how the disease is killing people," Kenneth Baillie, an intensive care doctor who is leading the study at the University of Edinburgh, told.

"I would bet my house on there being a very strong genetic component to individual risk," Baillie said.

Health minister Matt Hancock called on people to sign up to the programme. "If you're asked to sign up to the genomics trial which is being run by Genomics England, then please do, because then we can understand the genetic links. It's all part of building a scientific picture of this virus."

The genome is an organism's complete set of deoxyribonucleic acid, or DNA, and in humans it contains about three billion DNA base pairs.

But comparing them can be tough. There are four million to five million differences between any two people so scientists need a big sample, Baillie said.

"We don't know at a mechanistic level, at the level of molecules and cells, what are the events that are actually causing people to get sick and die from this disease," he said.

Baillie will work with the intensive care units across the UK, Genomics England and a global genetics research consortium known as the Genetics of Susceptibility and Mortality in Critical Care, or GenOMICC.

"By reading the whole genome we may able to identify variation that affects response to Covid-19 and discover new therapies that could reduce harm, save lives and even prevent future outbreaks," said Mark Caulfield, chief scientist at Genomics England.

Some answers could come as soon as in a few weeks from a study of almost 2,000 people already underway, Baillie said, though it is likely that testing more people will ensure that the signals they detect are genuine.

The results will be shared globally.

"Your chance of dying from an infection is very strongly encoded in your genes - much more strongly than your chances of dying from heart disease or cancer," Baillie said.

(Reuters)

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less